BRAF and neoplasm: The BRAF V600-specific inhibition of tumor growth across various tumor entities is a prime example of personalized cancer treatment (Subbiah et al. 2020) and depends on the availability of diagnostic biomarkers with predictive power for drug response (Chin et al. 2011).